Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Novo Nordisk landed in hot water with the FDA following ... the site is responsible for making Novo's once-weekly insulin icodec, which the FDA declined to approve in July over manufacturing ...

However, the CRL for insulin icodec in the United States is a setback for the company. Intense competition in the obesity sector also threatens Novo Nordisk’s market share. Patent expiry ...

“We believe in the potential of once-weekly basal insulin icodec for those living with diabetes who require basal insulin therapy,” said Martin Lange, head of development at Novo Nordisk.

However, the CRL for insulin icodec in the United States is a setback for the company. Intense competition in the obesity sector also threatens Novo Nordisk’s market share. Patent expiry ...

The results of the ONWARDS 2 trial of insulin icodec showed that it was as effective as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose ...

Suggested remit: To appraise the clinical and cost effectiveness of insulin icodec within its marketing authorisation for treating type 2 diabetes. Following an update from the company (Novo Nordisk), ...

Insulin icodec/semaglutide, or IcoSema, is a combination medication of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. It is injected once weekly.